Fig. 3
From: Current landscape of innovative drug development and regulatory support in China
R&D investment, new technologies, and new targets in China’s innovative drugs. a Internal R&D expenditure in China’s pharmaceutical manufacturing industry from 2019 to 2021, along with the year-on-year growth rates.160 b Comparison of the number and growth rates of First-in-Class (FIC), Fast-Follower (FF), Me-Too and all drugs under development in China in 2021 and 2024. c Number and proportion of various drug types under development in China in 2021 (inner ring) and 2024 (outer ring).44 d Number of drug pipelines in China and globally from 2019 to 2023, along with annual growth rates.177,178
